The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC).
The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues of the lung. The National Cancer Institute…
FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer
Friday, December 12, 2014
FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment